Asunercept in Patients With Severe COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

438

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

October 29, 2021

Study Completion Date

December 21, 2021

Conditions
COVID-19 Induced PneumoniaCovid19
Interventions
BIOLOGICAL

Asunercept

Asunercept (APG101) will be administered once per week as an i.v. infusion

Trial Locations (13)

Unknown

Republican Clinical Infectious Hospital n.a. professor A.F. Agafonov, Kazan'

Scientific Research lnstitute fоr Соmрlех lssues of Cardiovascular Diseases, Kemerovo

"Federal State Budgetary Educational Institution of Higher Education Kuban State Medical University of the Ministry of Health of the Russian Federation", Krasnodar

"State Budgetary Healthcare Institution Scientific Research Institute - Regional clinical hospital No. 1 n.a. professor S.V. Ochapovsky of the Ministry of Healthcare of Krasnodar Krai", Krasnodar

"State Budgetary Institution of Health of the Nizhny Novgorod Region Infectious Clinical Hospital No. 2 of Nizhny Novgorod", Nizhny Novgorod

Ryazan State Medical University n.a. academician I.P. Pavlov, Ryazan

"Saint Petersburg state budgetary healthcare institution City hospital of Saint George the great Martyr", Saint Petersburg

Hospital Universitario Infanta Leonor, Madrid

Hospital Universitario La Paz, Madrid

Hospital Universitario Ramón y Cajal, Madrid

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda

Hospital Universitario Infanta Sofia, San Sebastián de los Reyes

Hospital Clínico Universitario Lozano Blesa, Zaragoza

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Apogenix AG

INDUSTRY